Abstract
The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinsons disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
Keywords: CPCCOEt, positive allosteric modulators, signal transduction, Fenobam, LY354740
Current Neuropharmacology
Title: Allosteric Modulators for mGlu Receptors
Volume: 5 Issue: 3
Author(s): F. Gasparini and W. Spooren
Affiliation:
Keywords: CPCCOEt, positive allosteric modulators, signal transduction, Fenobam, LY354740
Abstract: The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinsons disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
Export Options
About this article
Cite this article as:
Gasparini F. and Spooren W., Allosteric Modulators for mGlu Receptors, Current Neuropharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157015907781695900
DOI https://dx.doi.org/10.2174/157015907781695900 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differential Mechanisms Underlying Antidepressant Responses of Ketamine and Imipramine
CNS & Neurological Disorders - Drug Targets Skin as a Novel Route for Allergen-specific Immunotherapy
Current Pharmaceutical Design Effectiveness of Nasal Continuous Positive Airway Pressure (CPAP) Therapy on Cardiovascular Outcomes in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS)
Current Respiratory Medicine Reviews L-Type Calcium Channels
Current Pharmaceutical Design Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives
CNS & Neurological Disorders - Drug Targets Sleep Terrors: An Updated Review
Current Pediatric Reviews Functional Roles of Synaptic and Extrasynaptic NMDA Receptors in Physiological and Pathological Neuronal Activities
Current Drug Targets Structure and Function of Water Molecules Buried in the Protein Core
Current Protein & Peptide Science The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Insight into the Role of Photoreception and Light Intervention for Sleep and Neuropsychiatric Behaviour in the Elderly
Current Alzheimer Research Risperidone Microemulsion for Transnasal Delivery: Pharmacodynamic and Pharmacokinetic Evaluation
Pharmaceutical Nanotechnology Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Drug Abuse, Brain Calcification and Glutamate-Induced Neurodegeneration
Current Drug Abuse Reviews Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Oral Appliances Improve Sleep Quality in Japanese Patients with Obstructive Sleep Apnea
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)